Choosing the right amniotic membrane wound dressing is one of the most consequential decisions wound care clinicians face each week. Two products have emerged at the forefront of this category: AmnioAMP (NextGen Biologics) and Rampart (fracture Medical). Both leverage the regenerative properties of human amniotic membrane, yet they differ meaningfully in processing methods, clinical outcomes, handling characteristics, and cost structure.
This guide provides a comprehensive AmnioAMP vs Rampart comparison designed for wound care physicians, nurse practitioners, and wound center administrators. We analyze published clinical data, handling protocols, storage logistics, and reimbursement considerations to help your team make an evidence-based selection.
Introduction to Amniotic Membrane Dressings in Wound Care
Human amniotic membrane has been used in wound care for over a century, but modern processing techniques have transformed it from a simple biological scaffold into an active regenerative therapy. Amniotic membranes contain a dense extracellular matrix rich in collagen types I, III, IV, and V, along with fibronectin, laminin, and hyaluronic acid.
More importantly, they carry a concentrated payload of growth factors including VEGF, PDGF, TGF-β, EGF, and bFGF—all of which play critical roles in angiogenesis, epithelialization, and modulation of the inflammatory cascade.
For clinicians treating chronic wounds that have stalled in the inflammatory phase, amniotic membrane dressings provide both the structural matrix and the biological signaling necessary to re-enter the proliferative phase. Understanding how different processing methods affect these components is essential to product selection.
Product Composition & Processing Methods
Cryopreserved vs Dehydrated Processing
The fundamental distinction between AmnioAMP and Rampart lies in their tissue processing methodology. Rampart utilizes a cryopreservation process that maintains the amniotic membrane at sub-zero temperatures throughout storage and transport. This method is designed to preserve the native three-dimensional architecture of the extracellular matrix and maintain the biological activity of embedded growth factors and cytokines. Cryopreservation requires continuous cold chain maintenance, typically at -20°C or lower, which introduces logistical complexity for wound centers without dedicated freezer capacity.
AmnioAMP, by contrast, employs an advanced dehydration process that removes moisture while preserving the structural integrity of key matrix proteins. Modern dehydration technology uses controlled humidity and temperature cycles to minimize denaturation of heat-sensitive growth factors. The resulting product is stable at room temperature for extended periods, dramatically simplifying inventory management and reducing the risk of product loss due to temperature excursions.
Cell Viability & Growth Factor Content
Published data on amniotic membrane products consistently shows that cryopreserved tissues retain a higher percentage of viable epithelial cells and stromal cells compared to dehydrated alternatives. Rampart's cryopreservation protocol is reported to maintain cell viability in the range of 60-80% post-thaw, whereas dehydrated products like AmnioAMP typically contain non-viable cells but retain the structural proteins and growth factor reservoirs bound to the extracellular matrix.
However, the clinical significance of cell viability in amniotic membrane dressings remains debated. Several peer-reviewed studies suggest that the paracrine signaling from growth factors and matrix-bound cytokines—not necessarily living cells—drives the majority of the wound healing response. Independent analyses have shown that properly dehydrated amniotic membranes retain 70-90% of their original growth factor concentrations, making them biologically active despite the absence of viable cells.
Clinical Performance Metrics
Closure Rates: Comparative Data
Clinical outcomes for amniotic membrane wound dressings vary significantly by wound etiology, chronicity, and patient comorbidities. Available comparative data for AmnioAMP vs Rampart suggests nuanced differences:
- Diabetic Foot Ulcers (DFU): Both products demonstrate closure rates exceeding 70% at 12 weeks when applied to appropriately debrided wounds. Rampart's cryopreserved format has shown marginally higher closure rates in wounds greater than 4 cm² in published case series, while AmnioAMP performs equivalently on smaller to moderate-sized ulcers.
- Venous Leg Ulcers (VLU): Closure rates for both products range from 60-75% at 12 weeks. AmnioAMP's room-temperature stability makes it particularly advantageous in outpatient wound clinics where consistent refrigeration may not be available.
- Pressure Injuries: Limited head-to-head data exists, though both products are used as adjunctive therapy in Stage III and Stage IV pressure injuries with promising outcomes.
Time-to-Heal Studies
Time-to-closure is a critical metric for wound care programs, particularly those operating under value-based reimbursement models. AmnioAMP has demonstrated median time-to-closure of 6-8 weeks for DFUs in clinical observations, while Rampart shows comparable timelines of 5-7 weeks in cryopreserved cohorts. The difference of 1-2 weeks is generally not statistically significant in most comparative analyses, suggesting that proper wound bed preparation and consistent re-application schedules are more impactful than the processing method alone.
Infection Prevention Efficacy
Amniotic membranes possess inherent antimicrobial properties mediated by defensins, elafin, and secretory leukocyte protease inhibitor (SLPI). Both AmnioAMP and Rampart retain these antimicrobial components, though cryopreservation may better preserve labile peptide structures. Clinical reports indicate infection rates below 5% for both products when applied to appropriately cleaned wound beds. For wounds with a history of recurrent infection or biofilm formation, either product serves as an effective barrier adjunct to systemic antibiotics.
Practical Application & Workflow
Placement Technique Comparison
Both AmnioAMP and Rampart are applied as inlay grafts following sharp debridement and hemostasis. The stromal (basement membrane) side is typically placed face-down toward the wound bed to maximize contact between the bioactive components and the healing tissue.
AmnioAMP's dehydrated format requires a brief rehydration step (typically 2-3 minutes in sterile saline or lactated Ringer's solution) before application, while Rampart requires thawing (10-15 minutes at room temperature or in a water bath) followed by careful handling to avoid membrane tearing during the wet state.
Storage Requirements & Shelf Life
Storage logistics represent one of the most significant differentiators in the AmnioAMP vs Rampart comparison. AmnioAMP's room-temperature stability eliminates the need for dedicated medical freezers, reduces energy costs, and prevents product waste from power outages or temperature monitoring failures. Rampart's cryopreserved format requires continuous -20°C storage, validated temperature monitoring, and careful thaw protocols. For high-volume wound centers managing inventory cold chain logistics across multiple clinic locations, AmnioAMP's supply chain simplicity often translates to fewer stockouts and reduced administrative burden.
Rehydration Protocol Differences
AmnioAMP requires rehydration in sterile saline for 2-3 minutes prior to application. The rehydration process is straightforward and can be performed directly at the bedside. Rampart's thawing process is similarly simple but requires advance planning—typically 10-15 minutes for complete thawing. Some wound centers report that thawed Rampart membranes are more fragile during handling, requiring additional care during placement. AmnioAMP's rehydrated membrane maintains slightly greater tensile strength during application, which can be advantageous for larger wounds or challenging anatomical locations.
Cost & Value Analysis
Cost Per Unit Comparison
Pricing for amniotic membrane products varies by surface area, purchase volume, and distributor agreements. Generally, Rampart's cryopreserved processing incurs higher manufacturing and storage costs, which are reflected in its per-unit pricing. AmnioAMP's dehydration process and room-temperature distribution typically result in a 10-20% lower cost per square centimeter compared to cryopreserved alternatives. For wound centers treating high volumes of chronic wounds, this per-unit differential compounds meaningfully over quarterly and annual purchasing cycles.
Bundle Pricing & Volume Discounts
Both manufacturers offer tiered pricing structures for wound centers committing to quarterly or annual purchase agreements. AmnioAMP frequently provides bundle pricing when combined with adjunctive wound care supplies, while Rampart's volume discounts are structured around committed cold-chain storage and distribution agreements. Wound center administrators should evaluate total cost of ownership—including freezer maintenance, temperature monitoring equipment, and waste from expired or temperature-compromised product—when comparing quoted prices.
Payer Reimbursement Considerations
Medicare and commercial payers generally reimburse reimbursement coding guidelines amniotic membrane applications under the same HCPCS codes (Q4122, Q4123, Q4124, etc.) regardless of processing method. Reimbursement rates are not differentiated between cryopreserved and dehydrated products, meaning wound centers using the lower-cost option typically realize higher margin per application. Prior authorization requirements are comparable for both products, though some regional MACs may request additional clinical documentation for repeat applications beyond the standard treatment protocol.
Product Selection Checklist for Wound Center Teams
When evaluating AmnioAMP vs Rampart for your wound care program, consider the following decision framework:
- Wound Population: If your center treats predominantly large (>4 cm²) or heavily exudative wounds, Rampart's cryopreserved matrix may offer marginal advantages. For moderate-sized ulcers and mixed wound populations, AmnioAMP performs equivalently.
- Infrastructure: Centres without reliable cold-chain infrastructure or those managing inventory across satellite locations will benefit significantly from AmnioAMP's room-temperature stability.
- Budget Constraints: When reimbursement is fixed, AmnioAMP's lower per-unit cost improves program margins without compromising clinical outcomes.
- Staff Workflow: Both products have minimal learning curves, but AmnioAMP's rehydration process may integrate more seamlessly into high-throughput clinic schedules.
| Feature | AmnioAMP | Rampart |
|---|---|---|
| Processing Method | Dehydrated | Cryopreserved |
| Storage Temperature | Room Temp | -20°C (Frozen) |
| Shelf Life | Up to 24 months | 12-18 months |
| Cold Chain Required | No | Yes |
| Cell Viability | Non-viable (matrix retained) | 60-80% viable |
| DFU Closure (12 wk) | ~70% | ~70-75% |
| Prep Time | 2-3 min rehydration | 10-15 min thaw |
| Relative Cost/cm² | Lower | Higher |
| Reimbursement Codes | Q4122-Q4124 | Q4122-Q4124 |
Ready to Evaluate AmnioAMP for Your Wound Center?
Request a product sample, schedule a clinical education session, or speak with our wound care specialists about integrating AmnioAMP into your treatment protocols.
Request Sample Kit